Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Fall on the Road
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adaptimmune Ther ADR
(NQ:
ADAP
)
1.470
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.470
Bid (Size)
1.400 (14)
Ask (Size)
1.500 (50)
Prev. Close
1.470
Today's Range
1.470 - 1.470
52wk Range
0.4200 - 2.050
Shares Outstanding
1,480,950,456
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 08, 2024
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Via
Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
March 08, 2024
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Performance
YTD
+97.05%
+97.05%
1 Month
+16.67%
+16.67%
3 Month
+227.03%
+227.03%
6 Month
+98.51%
+98.51%
1 Year
+34.86%
+34.86%
More News
Read More
Adaptimmune Therapeutics Earnings Preview
March 05, 2024
Via
Benzinga
Analyst Expectations for Adaptimmune Therapeutics's Future
August 10, 2023
Via
Benzinga
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 06, 2024
Via
InvestorPlace
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
March 06, 2024
Via
Newsfile
Topics
Economy
Exposures
Product Safety
Supply Chain
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Via
Newsfile
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
February 21, 2024
Via
Newsfile
Earnings Scheduled For March 6, 2024
March 06, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
January 31, 2024
Via
Newsfile
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
January 29, 2024
Via
Benzinga
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
January 04, 2024
Via
Newsfile
Exposures
Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
December 15, 2023
Via
Benzinga
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
December 06, 2023
Via
Newsfile
Exposures
Product Safety
Adaptimmune Receives Transfer of IND for Lete-cel Program
November 29, 2023
Via
Newsfile
Adaptimmune Reports Third Quarter Financial Results and Business Update
November 08, 2023
Via
Newsfile
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
November 08, 2023
Via
Newsfile
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
October 31, 2023
Via
Newsfile
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
October 31, 2023
Via
Newsfile
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
October 25, 2023
Via
Newsfile
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
October 23, 2023
Via
Newsfile
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
September 11, 2023
Via
Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
August 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 24, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.